Measurement of MDRI Gene Expression by Real-Time Quantitative RT-PCR Using the LightCyc1er Instrument EiD
Conclusion
Our results indicate that this assay is a simple, reliable, and sensitive method for
quantifying MDRl expression at the mRNA level with excellent turnaround time
(about 45 min) after cDNA preparation. This method should be suitable for routine clinical use and for large series of oncological studies.
References
1. Ling V (1997) Multidrug resistance: molecular mechanisms and clinical relevance. Cancer
Chemother PharmacoI40[Suppl):S3-S8
2. Chin KV et al. (1993) Function and regulation of the human multidrug resistance gene. Adv
Cancer Res 60:157-180
3. Leith CP, Kopecky KJ, Godwin Jet al. (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups
with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group
study. Blood 89:3323-3329
4. Chevillard S, Vielh PH, Validire P et al. (1997) French multicentric evaluation of MDR1 gene
expression by RT-PCR in leukemia and solid tumors. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumor.
Leukemia 11:1095-1106
5. Beck WT, Grogan TM, Willman, CL et al. (1996) Method to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendation. Cancer Res
56:3010-3020
6. Norgaard JM, Bukh A, Langkjer ST, Clausen N, Palshof T, Hokland P (1998) MDR1 gene
expression and drug resistance of AML cells. Br J Haematol100:534-540
7. Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP (1997) Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 20:l30-l38
8. Caplin BE, Rasmussen RP, Bernard PS, Wittwer CT (1999) LightCycler hybridization probes.
Biochemica 1:5-8
Conclusion
Our results indicate that this assay is a simple, reliable, and sensitive method for
quantifying MDRl expression at the mRNA level with excellent turnaround time
(about 45 min) after cDNA preparation. This method should be suitable for routine clinical use and for large series of oncological studies.
References
1. Ling V (1997) Multidrug resistance: molecular mechanisms and clinical relevance. Cancer
Chemother PharmacoI40[Suppl):S3-S8
2. Chin KV et al. (1993) Function and regulation of the human multidrug resistance gene. Adv
Cancer Res 60:157-180
3. Leith CP, Kopecky KJ, Godwin Jet al. (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups
with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group
study. Blood 89:3323-3329
4. Chevillard S, Vielh PH, Validire P et al. (1997) French multicentric evaluation of MDR1 gene
expression by RT-PCR in leukemia and solid tumors. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumor.
Leukemia 11:1095-1106
5. Beck WT, Grogan TM, Willman, CL et al. (1996) Method to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendation. Cancer Res
56:3010-3020
6. Norgaard JM, Bukh A, Langkjer ST, Clausen N, Palshof T, Hokland P (1998) MDR1 gene
expression and drug resistance of AML cells. Br J Haematol100:534-540
7. Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP (1997) Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 20:l30-l38
8. Caplin BE, Rasmussen RP, Bernard PS, Wittwer CT (1999) LightCycler hybridization probes.
Biochemica 1:5-8
Précédent